Characterization of the Myc collaborating oncogenes Bmi1 and Gfi1
Scheijen, G.P.H.
Publication date
2001
Link to publication
Citation for published version (APA):
Scheijen, G. P. H. (2001). Characterization of the Myc collaborating oncogenes Bmi1 and
Gfi1.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Publications
Publications
Publications
Publications
1. van Lohuizen, M., S. Verbeek, B. Scheijen, E. Wientjens, H. van der Gulden, and A. Berns. 1991. Identification of cooperating oncogenes in E\x-myc transgenic mice by provirus tag-ging. Cell 65: 737-752.
2. Scheijen, B., J. Jonkers, D. Acton, and A. Berns. 1997. Characterization of pal-1, a com-mon proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pirn-J transgenic mice. J Virol 71: 9-16.
3. Berns, A., H. Mikkers, P. Krimpenfort, J. Allen, B. Scheijen. and J. Jonkers. 1999. Identifi-cation and characterization of collaborating oncogenes in compound mutant mice. Cancer Res 59: 1773s- 1777s.
4. Jacobs, J.J., B. Scheijen. J.W. Voncken, K. Kieboom, A. Berns, and M. van Lohuizen. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apop-tosis via INK4a/ARF. Genes Dev 13: 2678-2690.
5. Scheijen, B.. and A. Berns. Submitted. Retroviral insertions in the blal locus result in long-range activation of the bmil proto-oncogene in B cell lymphomas.
6. Scheijen, B.. H. Jacobs and A. Berns. Submitted. Gfil promotes thymocyte selection at dif-ferent stages and inhibits death by neglect, during negative selection and in common re-ceptor y-chain deficient mice.
7. Scheijen, B.. and A. Berns. Submitted. Chronic Myeloid Leukemia-like syndrome and lymphoblastic T cell tumors in mice transgenic for the transcription factor Gfil.
8. Scheijen, B.. and A. Berns. Submitted. E\i-myc and gfil collaborate in T cell lymphomage-nesis by targeting a p53- and Bcl-2-independent apoptosis pathway.
